Literature DB >> 22020922

Characterization of a heterodimeric Smac-based peptide that features sequences specific to both the BIR2 and BIR3 domains of the X-linked inhibitor of apoptosis protein.

Kelsey F Speer1, Charles L Cosimini, Kathryn E Splan.   

Abstract

XIAP, an important regulator of apoptosis, has emerged as a target for the development of cancer therapeutics. The homodimeric Smac protein simultaneously binds to both the BIR2 and BIR3 domains of XIAP. Peptide-based dimeric compounds that mimic the binding mode of Smac show promise as XIAP antagonists. Herein we characterize the first example of a Smac mimetic that incorporates a peptide sequence specific for BIR2. We show that the tetrapeptide motif Ala-Glu-Ala-Val has a higher affinity for BIR2 than the BIR3-specific sequence Ala-Val-Pro-Phe, and we compare the binding characteristics of a heterodimeric peptide containing both tetrapeptide motifs to those of a homodimeric peptide featuring only AVPF. Despite the enhanced affinity of AEAV (relative to AVPF) for BIR2, the heterodimeric peptide displays only a slightly higher affinity for XIAP relative to its homodimeric counterpart. Enhanced affinity of both dimers relative to the tetrapeptide AVPF is largely maintained even when the BIR2 binding groove is modified, implying that hydrophobic contacts afforded by the second peptide motif need not necessarily be made at the BIR2 binding groove to contribute substantial binding energy. Finally, we use mutagenesis to show that the difference in sequence specificity observed between the two domains is primarily owing to steric bulk introduced at the BIR2 site by lysine 206. Replacement of K206 at BIR2 with glycine, the corresponding residue in BIR3, restores the majority of the affinity for the AVPF motif exhibited by BIR3. The implications of these finding in the development of XIAP antagonists are discussed. © 2011 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 98: 122-130, 2012.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22020922     DOI: 10.1002/bip.21732

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  3 in total

1.  Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP.

Authors:  Robert J Ardecky; Kate Welsh; Darren Finlay; Pooi San Lee; Marcos González-López; Santhi Reddy Ganji; Palaniyandi Ravanan; Peter D Mace; Stefan J Riedl; Kristiina Vuori; John C Reed; Nicholas D P Cosford
Journal:  Bioorg Med Chem Lett       Date:  2013-05-14       Impact factor: 2.823

2.  The structure of XIAP BIR2: understanding the selectivity of the BIR domains.

Authors:  Christine Lukacs; Charles Belunis; Robert Crowther; Waleed Danho; Lin Gao; Barry Goggin; Cheryl A Janson; Shirley Li; Stacy Remiszewski; Andrew Schutt; Manish K Thakur; Saroj K Singh; Srinivasan Swaminathan; Rajat Pandey; Rajiv Tyagi; Ramachandraiah Gosu; Ajith V Kamath; Andreas Kuglstatter
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2013-08-15

3.  The TwistDock workflow for evaluation of bivalent Smac mimetics targeting XIAP.

Authors:  Qingsheng Huang; Yin Peng; Yuefeng Peng; Dan Wei; Yanjie Wei; Shengzhong Feng
Journal:  Drug Des Devel Ther       Date:  2019-04-26       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.